Effectiveness of 10 and 13-valent pneumococcal conjugate vaccines against invasive pneumococcal disease in European children: SpIDnet observational multicentre study.
Name:
Publisher version
View Source
Access full-text PDFOpen Access
View Source
Check access options
Check access options
Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Authors
Savulescu, CameliaKrizova, Pavla
Valentiner-Branth, Palle
Ladhani, Shamez
Rinta-Kokko, Hanna
Levy, Corinne
Mereckiene, Jolita
Knol, Mirjam
Winje, Brita A
Ciruela, Pilar
de Miguel, Sara
Guevara, Marcela
MacDonald, Laura
Kozakova, Jana
Slotved, Hans-Christian
Fry, Norman K
Pekka Nuorti, J
Danis, Kostas
Corcoran, Mary
van der Ende, Arie
Vestrheim, Didrik F
Munoz-Almagro, Carmen
Sanz, Juan-Carlos
Castilla, Jesus
Smith, Andrew
Colzani, Edoardo
Pastore Celentano, Lucia
Hanquet, Germaine
Type
ArticleOther
Language
en
Metadata
Show full item recordTitle
Effectiveness of 10 and 13-valent pneumococcal conjugate vaccines against invasive pneumococcal disease in European children: SpIDnet observational multicentre study.Published in
Vaccine 2022; 40(29):3963-3974PMID
35637067ae974a485f413a2113503eed53cd6c53
10.1016/j.vaccine.2022.05.011
Scopus Count
Collections
Related articles
- Effectiveness of the seven-valent and thirteen-valent pneumococcal conjugate vaccines in England: The indirect cohort design, 2006-2018.
- Authors: Andrews N, Kent A, Amin-Chowdhury Z, Sheppard C, Fry N, Ramsay M, Ladhani SN
- Issue date: 2019 Jul 26
- A systematic review of invasive pneumococcal disease vaccine failures and breakthrough with higher-valency pneumococcal conjugate vaccines in children.
- Authors: Mungall BA, Hoet B, Nieto Guevara J, Soumahoro L
- Issue date: 2022 Feb
- Effect of high-valency pneumococcal conjugate vaccines on invasive pneumococcal disease in children in SpIDnet countries: an observational multicentre study.
- Authors: Savulescu C, Krizova P, Lepoutre A, Mereckiene J, Vestrheim DF, Ciruela P, Ordobas M, Guevara M, McDonald E, Morfeldt E, Kozakova J, Varon E, Cotter S, Winje BA, Munoz-Almagro C, Garcia L, Castilla J, Smith A, Henriques-Normark B, Celentano LP, Hanquet G, SpIDnet group
- Issue date: 2017 Aug
- Long-term Impact of a "3 + 0" Schedule for 7- and 13-Valent Pneumococcal Conjugate Vaccines on Invasive Pneumococcal Disease in Australia, 2002-2014.
- Authors: Jayasinghe S, Menzies R, Chiu C, Toms C, Blyth CC, Krause V, McIntyre P
- Issue date: 2017 Jan 15
- Comparison of the Impact of Pneumococcal Conjugate Vaccine 10 or Pneumococcal Conjugate Vaccine 13 on Invasive Pneumococcal Disease in Equivalent Populations.
- Authors: Naucler P, Galanis I, Morfeldt E, Darenberg J, Örtqvist Å, Henriques-Normark B
- Issue date: 2017 Nov 13
Related items
Showing items related by title, author, creator and subject.
-
Twelve years of pneumococcal conjugate vaccination in the Netherlands: Impact on incidence and clinical outcomes of invasive pneumococcal disease.Vestjens, Stefan M T; Sanders, Elisabeth A M; Vlaminckx, Bart J; de Melker, Hester E; van der Ende, Arie; Knol, Mirjam J (2019-10-08)
-
Impact and effectiveness of the 10-valent pneumococcal conjugate vaccine on invasive pneumococcal disease among children under 5 years of age in the Netherlands.Peckeu, L; van der Ende, A; de Melker, H E; Sanders, E A M; Knol, M J (2020-11-23)
-
Similar impact and replacement disease after pneumococcal conjugate vaccine introduction in hospitalised children with invasive pneumococcal disease in Europe and North America.Palmu, Arto A; De Wals, Philippe; Toropainen, Maija; Ladhani, Shamez N; Deceuninck, Geneviève; Knol, Mirjam J; Sanders, Elisabeth A M; Miller, Elizabeth (2021-02-18)